Please assess the completion status of the following clinical trial:

Trial Title: Viral Etiology of Severe Acute Respiratory InFection in CriticallY Ill Patients Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults (≥14 years old) patients~* A clinical presentation consistent with community-acquired SARI/pneumonia~* AND admitted to the ICU because of respiratory failure or sepsis~* AND is invasively mechanically ventilated.~Exclusion Criteria:~* Diagnosed with COVID-19~* Duration of illness \> 14 days since symptom onset~* Did not meet inclusion criteria in the first 48 hrs of admission to the ICU.~* Patient already enrolled in the study~* Participant or legal guardian refuses to participate in the study.~* Diagnosis is not related to SARI~* Enrolled in interventional trial of investigational therapeutics for pneumonia.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Severe Acute Respiratory Infection (SARI) (Type: None): Nasopharyngeal swab, MINI BAL samples, Serum samples, Plasma sample, and Blood sample (RNA) will be collected from patients on day 0 (baseline) of enrollment, and on day 14 of enrollment.~SAMPLING PROCEDURES:~1. Nucleic acid extraction~2. Polymerase chain reaction (PCR) 2.1 Testing for MERS-CoV will be performed by RT-PCR 2.2 We will test for Infleunza H and N PCR for influenza H 2.3 We will also test for a panel of viruses using PCR multiplex that includes influenza A ; influenza B ; influenza C ; influenza A (H1N1) swl ; parainfluenza viruses 1, 2, 3 and 4 ; coronaviruses NL63, 229E, OC43 and HKU1; human metapneumoviruses A/B; rhinovirus ;respiratory syncytial viruses A and B; adenovirus; enterovirus; parechovirus; bocavirus.~3.16S PCR and sanger sequencing for bacterial detection 4.Metagenomics /Next Generation Sequencing 5.Microbiome bioinformatics analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).